

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VPI/SW/002 CIP2 FWC DIV2 CON	SERIAL NO. 09/670,106
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS P. Sleath et al.	CONFIRMATION NO. 5809
		FILING DATE September 26, 2000	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CM	Arsenijevic et al., Préparation simple de la DL- α -asparagine. Comptes Rendus 256, p. 4039 (1963). /
	Blundell et al., Retroviral Proteinases: A Second Front Against AIDS. Nature 337, pp. 596-597 (1989). /
	Cohen, Designing Antisense Oligonucleotides as Pharmaceutical Agents. Trends Pharmaceut. Sci., 10, pp. 435-437 (1989). /
	Manson et al., Modulation of Interleukin 1 β Gene Expressing Using Antisense Phosphorothioate Oligonucleotides. Lymphokine Res., 9, pp. 35-42 (1990). /
	Kobayashi et al., Identification of Calcium-Activated Neutral Protease as a Processing Enzyme of Human Interleukin 1 α . Proc Natl. Acad. Sci. USA, 87, pp. 5548-5552 (1990). /
	Matsoukas et al., Synthesis of L-Prolyl-L-Leucylglycine Alkylamides. J. Org. Chem. 42, pp. 2105-2108 (1977). /
U	Rich, Inhibitors of Aspartic Proteinases. in Proteinase Inhibitors (Barret and Salvesan, eds.) Elsevier Science Publishers, pp. 180-217 (1986). /
	Seelmeier et al. Human Immunodeficiency Virus Has an Aspartic-type Protease That Can be Inhibited by Pepstatin A. Proc. Natl. Acad. Sci. USA, 85, pp. 6612-6616 (1988). /
	Yamashiro et al. Synthesis of a Pentekontapeptide with High Lipolytic Activity Corresponding to the Carboxyl-Terminal Fifty Amino Acids of Ovine β -Lipotropin. Proc. Natl. Acad. Sci. USA, 72, pp. 4945-4949 (1974). /

EXAMINER

CM

DATE CONSIDERED

1-25-04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.